GENEVA, SWITZERLAND, September 11, 2019: Hôpitaux Universitaires Genève (HUG) – a leading Swiss healthcare provider today announced that HUG will become the first European university hospital to use the IBM Watson Health's precision oncology offering, Watson for Genomics®, an artificial intelligence (AI) tool that enables oncologists to provide patients with more personalized, evidence-based cancer care.
Using information extracted from peer-reviewed articles and validated by experts, Watson for Genomics® produces a report for physicians classifying genetic alterations in a patient's tumor and providing associated therapies and clinical trials for the actionable ones. By implementing this tool, physicians at HUG will be able to more quickly interpret massive bodies of genomic data for various cancer types and scale precision oncology for their patients.
"As the first European hospital to adopt Watson for Genomics® we will further help our physicians provide more personalized cancer care and streamline variability for genomic reporting, which we believe may improve outcomes for our patients," said Rudolph Meyer, Deputy Chief Information Officer, HUG. "We remain very committed to the fight against cancer, including utilizing the best technological advances in medicine, such as AI, and participating in ongoing, quality academic research.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
With 18 million diagnoses each year,cancer has a heavy human toll, as well as a high health system cost. Patients can face exhausting, lengthy and confusing treatment regimens, while oncologists are responsible for staying up to date on an ever-growing body of medical literature and genomic data to identify the best care plan for each individual patient.
"We are pleased to partner with Hôpitaux Universitaires Genève to bring IBM Watson for Genomics® to Europe, and we look forward to working with HUG to help their physicians focus on what matters most – their patients – and make better and informed decisions that aid in their treatment and care," says Nathan Levitan, M.D., Chief Medical Officer Oncology & Genomics, IBM Watson Health. "This technology provides clinicians the ability to find actionable genomic insights that manual interpretationmay miss while also saving clinician time– completing analysis of whole gene and RNA-sequencing results in ten minutes compared to what would take 160 hours manually."
The news was released at the Intelligent Healthconference in Basel, Switzerland, the world's leading AI in medicine summit that connects global leaders at the forefront of health innovation.